.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,248,195

« Back to Dashboard

Claims for Patent: 9,248,195

Title:Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
Inventor(s): Rariy; Roman V. (Allston, MA), Fleming; Alison B. (North Attleboro, MA), Hirsh; Jane (Wellesley, MA), Klibanov; Alexander M. (Boston, MA)
Assignee: Collegium Pharmaceutical, Inc. (Canton, MA)
Application Number:14/054,513
Patent Claims: 1. A method of administering an abuse-deterrent pharmaceutical composition comprising orally administering to a patient in need thereof an abuse-deterrent oral dosage form comprising a plurality of microparticles, where each microparticle comprises: a fatty acid salt of one or more drugs prone to abuse; and one or more carrier material(s) comprising fats, fatty substances, waxes, wax-like substances or mixtures thereof wherein the oral dosage form retards the release of the one or more drugs prone to abuse, even if the physical integrity of the dosage form is compromised and the compromised dosage form is placed in water.

2. A method of administering an abuse-deterrent pharmaceutical composition comprising orally administering to a patient in need thereof an abuse-deterrent oral dosage form comprising a plurality of microparticles, where each microparticle comprises: a solidified solution of a fatty acid salt of one or more drugs prone to abuse; and one or more carrier material(s) comprising fats, fatty substances, waxes, wax-like substances or mixtures thereof.

3. The method of claim 2, wherein the oral dosage form retards the release of the one or more drugs prone to abuse, even if the physical integrity of the dosage form is compromised and the compromised dosage form is placed in water.

4. The method of claim 1 or 2, wherein the one or more drugs prone to abuse is an opioid.

5. The method of claim 4, wherein the opioid is an opioid agonist.

6. The method of claim 5, wherein the opioid agonist is hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone or tramadol.

7. The method of claim 1 or 2, wherein the fatty acid salt is the stearate, palmitate or the myristate fatty acid salt.

8. The method of claim 1 or 2, wherein the one or more carrier materials comprise myristic acid, stearic acid, palmitic acid, beeswax, carnauba wax, hydrogenated oil or mixtures thereof.

9. The method of claim 1 or 2, wherein the oral dosage form is a capsule or a tablet.

10. The method of claim 1 or 2, wherein the oral dosage form further comprises an antioxidant.

11. The method of claim 10, wherein the antioxidant comprises butylated hydroxytoluene (BHT); ascorbic acid, its salts and esters; Vitamin E, tocopherol and its salts; sodium metabisulphite; cysteine; citric acid; propyl gallate; butylated hydroxyanisole (BHA); or combinations thereof.

12. The method of claim 1 or 2, wherein each microparticle further comprises an enteric coat.

13. The method of claim 1 or 2, wherein the oral dosage form is a controlled-release oral dosage form.

14. The method of claim 1 or 2, wherein each microparticle further comprises a pharmaceutically acceptable surfactant.

15. The method of claim 1 or 2, wherein the microparticles are spherical.

16. The method of claim 1 or 2, wherein the one or more drugs prone to abuse is a stimulant.

17. The method of claim 16, wherein the stimulant is amphetamine, methamphetamine or methylphenidate.

18. The method of claim 2, wherein the one or more drugs prone to abuse is uniformly dispersed in the carrier material of each microparticle.

19. The method of claim 2, wherein each microparticle comprises one or more fatty acids as carrier materials in an amount sufficient to solubilize the one or more drugs prone to abuse in the carrier material(s).

20. A method for the management of pain comprising administering to a patient in need thereof an abuse-deterrent oral dosage form comprising a plurality of microparticles, where each microparticle comprises: a fatty acid salt of one or more drugs prone to abuse; and one or more carrier material(s) comprising fats, fatty substances, waxes, wax-like substances or mixtures thereof wherein the oral dosage form retards the release of the one or more drugs prone to abuse, even if the physical integrity of the dosage form is compromised and the compromised dosage form is placed in water; and wherein the one or more drugs prone to abuse is an opioid.

21. The method of claim 20, wherein the opioid is an opioid agonist.

22. The method of claim 21, wherein the opioid agonist is hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone or tramadol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc